December 1, 2016 - By Nellie Frank · 0 Comments
Dec 1 is a negative day so far for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) as the ETF is active during the day after losing 2.86% to hit $41.5 per share. The exchange traded fund has 420.79M net assets and 4.41% volatility this month.
Over the course of the day 531,145 shares traded hands, as compared to an average volume of 731,130 over the last 30 days for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB).
The ETF is -35.90% of its 52-Week High and 39.12% of its low, and is currently having ATR of 2.4. This year’s performance is -33.89% while this quarter’s performance is -7.06%.
The ETF’s YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.
More notable recent ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) news were published by: Etfdailynews.com which released: “Biotech ETF Slide Likely To Continue” on September 23, 2015, also Etfdailynews.com with their article: “The Best Biotech ETF To Buy and One To Avoid [iShares NASDAQ Biotechnology …” published on October 14, 2014, Benzinga.com published: “ProShares Releases 2 New Leveraged Biotech ETFs” on June 23, 2015. More interesting news about ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) were released by: Nasdaq.com and their article: “The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International …” published on September 30, 2015 as well as Seekingalpha.com‘s news article titled: “Biotech Strategy Following Brexit: Run, Don’t Walk” with publication date: June 27, 2016.
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The ETF has a market cap of $420.79 million. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. It currently has negative earnings. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank